OBLITERATE Study for Oligoprogressive Lung and Thoracic Cancers
This study is for people with non-small cell lung cancer or small cell lung cancer that has started to grow in a few places (oligoprogressive). It's testing if adding local treatments like Stereotactic Ablative Radiotherapy (SABR) or interventional radiology (IR) ablation therapy to your current cancer medicine helps control the disease. The main goal is to see how many people have their disease controlled three months after these local treatments. You can join if you are 18 or older. The current recruitment status is unclear.
- Study design
- This is a Phase 2 study at one location, planning to enroll 100 participants. It is a pragmatic study, meaning it aims to reflect real-world medical practice.
- What's involved
- Participants will receive local ablative therapy in addition to their systemic therapy. You will be followed for up to 5 years after the local ablative therapy.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 5 years after receiving ablative local therapy.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Xiao Zhao, MD · PRINCIPAL_INVESTIGATOR · University of California, Davis
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of participants with controlled disease3 months from the first day of ablative local therapy
Number of participants with controlled disease at 3 months, defined as continuation in systemic cancer therapy without any changes or permanent discontinuation for 3 months following first day of ablative local therapy